 | • レポートコード：B-MOR-040907 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、すい臓がんの治療薬および診断の世界市場について調べ、すい臓がんの治療薬および診断の世界規模、市場動向、市場環境、治療薬別（パクリタキセルアルブミン（アブラキサン）、エベロリムス（アフィニトール）、塩酸エルロチニブ（タルセバ）、フルオロウラシル、塩酸ゲムシタビン、塩酸イリノテカン、マイトマイシンC、リンゴ酸スニチニブ（スーテント）、その他）分析、診断別（イメージング、生体組織検査、内視鏡検査、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・すい臓がんの治療薬および診断の世界市場インサイト ・すい臓がんの治療薬および診断の世界市場環境 ・すい臓がんの治療薬および診断の世界市場動向 ・すい臓がんの治療薬および診断の世界市場規模 ・すい臓がんの治療薬および診断の世界市場規模：治療薬別（パクリタキセルアルブミン（アブラキサン）、エベロリムス（アフィニトール）、塩酸エルロチニブ（タルセバ）、フルオロウラシル、塩酸ゲムシタビン、塩酸イリノテカン、マイトマイシンC、リンゴ酸スニチニブ（スーテント）、その他） ・すい臓がんの治療薬および診断の世界市場規模：診断別（イメージング、生体組織検査、内視鏡検査、その他） ・すい臓がんの治療薬および診断の世界市場：地域別市場規模・分析 ・すい臓がんの治療薬および診断の北米市場規模・予測 ・すい臓がんの治療薬および診断のアメリカ市場規模・予測 ・すい臓がんの治療薬および診断のヨーロッパ市場規模・予測 ・すい臓がんの治療薬および診断のアジア市場規模・予測 ・すい臓がんの治療薬および診断の日本市場規模・予測 ・すい臓がんの治療薬および診断の中国市場規模・予測 ・すい臓がんの治療薬および診断のインド市場規模・予測 ・すい臓がんの治療薬および診断の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global pancreatic cancer therapeutics & diagnostics market was valued at USD 2,272.40 million in 2017, and is expected to witness a CAGR 5.6% during 2018 to 2023 (henceforth referred to as the forecast period). Pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of the cancer deaths and in Europe, pancreatic cancer is the 4th leading cause of death.
Accelerating the therapy for treating the pancreatic cancer
A number therapies has been accelerated in the very less span of time and chemotherapy is the most common form of treatment provided by medical practitioners and other emerging chemotherapies are for the advanced pancreatic cancer combined with agents already approved for use. The one treatment commonly used for the pancreatic cancer is radiation therapy. Radiotherapy uses high energy x-rays (radiation) to destroy the cancer cells. The latest Cancer Research UK states that around 9,400 people are diagnosed with pancreatic cancer each year in the UK and around 8,800 people die from the disease each year and 514 patients are suffering in Europe with pancreatic cancer. Following the surgery, all the patients are been treated with chemo radiotherapy which is increasing the usage of its market.
Drugs and its side effects
As many drugs have been prescribed for the treatment of pancreatic cancer and those drugs have adverse effects, ranging from mild to severe. Very mild fever, loss in appetite, vomiting, and skin rashes can be related with the usage of most of the drugs used to treat pancreatic cancer. There are many list of drugs such as; Tarceva, a drug which is used to treat pancreatic cancer, can lead to pregnancy-related problems, and sometimes, even harm the fetus and can also cause complete failure of liver and kidney functioning. People who have used Afinitor as a treatment regimen for pancreatic cancer have reported losses in appetite, multiple infections, hypercholesterolemia, headache, pneumonitis, stomatitis, diarrhea, asthenia, weight loss etc. The possibility of multiple side effects, with a few that can even cause death results in the reluctance in prescribing drugs to patients. The usage of drugs causes its side effects and acts as a major restraint to the global pancreatic cancer drugs market.
China becomes one of the fastest growing market for Pancreatic Cancer
According to the 2015 oncology annals, pancreatic cancer in China is the 9th/6th leading death cause from cancer for men and woman, respectively. Around 90,000 patients were diagnosed with the pancreatic cancer and 79,400 patients in China with pancreatic cancer died in 2015. Despite many recent improvements of diagnostic techniques, most pancreatic cancer patients were diagnosed at advanced states. Radical resection, alone or in combination with other therapy, is the only way to eliminate pancreatic cancer. Only 10%–20% of patients with pancreatic cancer, who have radical resection, can survive up to 5 years. So, it is necessary to underscore the need for better preoperative staging and more effective systemic therapy. The rising rate of pancreatic cancer and improving access to cancer diagnosis and treatment centers in China are the major driving contributing factors which lead to the exceptional growth of Pancreatic Cancer Therapeutics and Diagnostics Market in China.
Key Developments in the Market
• October, 2017: Amgen and CytomX Therapeutics Announce Strategic Collaboration in Immuno-Oncology
• September, 2017: FDA Approves Amgen and Allergan’s MVASI™ (bevacizumab-awwb) For the Treatment of Five Types of Cancer
• May, 2017: NantKwest, NantCell to Test NANT Vaccine in Phase 1/2 Trial for Pancreatic Cancer Patients
Key players of this market are ELI LILLY, AMGEN Inc., F. HOFFMANN-LA ROCHE, CLOVIS ONCOLOGY Inc., PFIZER, NOVARTIS AG and THRESHOLD PHARMACEUTICALS Inc.
Reasons to Purchase this Report
• Current and future pancreatic cancer market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3 months analyst support along with the Market Estimate sheet in excel.
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. INTRODUCTION
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTER’S FIVE FORCES ANALYSIS
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 INCREASING INCIDENCE AND PREVALENCE OF PANCREATIC CANCER
6.1.2 UNMET THERAPY NEEDS FOR PANCREATIC CANCER
6.1.3 ADVANCEMENTS IN MOLECULAR BIOLOGY AND DEVELOPMENT OF DRUGS
6.2 MARKET RESTRAINTS
6.2.1 DRUG TOXICITY OR DRUG SIDE EFFECTS
6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENTS
6.3 OPPORTUNITIES
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 SEGMENTATION-BY THERAPEUTIC
7.1.1 PACLITAXEL ALBUMIN (ABRAXANE)
7.1.2 EVEROLIMUS (AFINITOR)
7.1.3 ERLOTINIB HYDROCHLORIDE (TARCEVA)
7.1.4 FLUOROURACIL
7.1.5 GEMCITABINE HYDROCHLORIDE
7.1.6 IRINOTECAN HYDROCHLORIDE
7.1.7 MITOMYCIN C
7.1.8 SUNITINIB MALATE (SUTENT)
7.1.9 OTHERS
7.2 BY DIAGNOSTIC
7.2.1 IMAGING
7.2.2 BIOPSY
7.2.3 ENDOSCOPY
7.2.4 OTHERS
7.3 SEGMENTATION-BY GEOGRAPHY
7.3.1 NORTH AMERICA
7.3.1.1 UNITED STATES
7.3.1.2 CANADA
7.3.1.3 MEXICO
7.3.2 EUROPE
7.3.2.1 FRANCE
7.3.2.2 GERMANY
7.3.2.3 UNITED KINGDOM
7.3.2.4 ITALY
7.3.2.5 SPAIN
7.3.2.6 REST OF EUROPE
7.3.3 ASIA-PACIFIC
7.3.3.1 CHINA
7.3.3.2 JAPAN
7.3.3.3 INDIA
7.3.3.4 AUSTRALIA & NEW ZEALAND
7.3.3.5 SOUTH KOREA
7.3.3.6 REST OF ASIA-PACIFIC
7.3.4 MIDDLE EAST & AFRICA
7.3.4.1 GCC
7.3.4.2 SOUTH AFRICA
7.3.4.3 REST OF THE MIDDLE EAST & AFRICA
7.3.5 SOUTH AMERICA
7.3.5.1 BRAZIL
7.3.5.2 ARGENTINA
7.3.5.3 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS & ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. KEY PLAYERS
9.1 GENENTECH INC.
9.2 ELI LILLY
9.3 PFIZER
9.4 AMGEN INC.
9.5 CELGENE CORPORATION
9.6 NOVARTIS INTERNATIONAL AG
9.7 IPSEN PHARMACEUTICALS
9.8 BIORAD LABORATORIES INC.
9.9 F. HOFFMANN-LA ROCHE
9.10 CLOVIS ONCOLOGY INC.,
9.11 BECKMAN COULTER
10. FUTURE OF THE MARKET